Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Mund Kiefer Gesichtschir ; 8(2): 83-92, 2004 Mar.
Artigo em Alemão | MEDLINE | ID: mdl-15045531

RESUMO

BACKGROUND: The alteration of the N-terminal amino acid sequence of BMP-2 allows modification of heparin binding of the new protein. This leads to a change in the local retention time at the site of implantation. Mutants with increased (T3, T4) and with no binding (EHBMP-2) to heparin were assessed for their osteoinductivity in vivo and compared with the wild type BMP-2. METHODS: Cylindrical collagenous carriers (diameter = 5 mm, height = 10) were loaded with different concentrations (0.25-4 micro g) of the proteins. Following intramuscular implantation into the hind legs, the bone formation was measured in radiographic follow-ups. After 28 days the newly formed bone was characterized histologically. RESULTS: Elimination of the heparin binding leads to massive reduction in osteoinductivity. On the other hand, an increase in the heparin binding leads to enhancement in the osteoinductive properties, resulting in faster bone formation with a higher yield. CONCLUSION: It could be shown for the first time that modifications of BMP-2 by gene technology can lead to proteins with enhanced binding to components of the extracellular matrix. The resulting prolonged retention time at the implantation site results in an increased osteoinductivity compared with the wild type.


Assuntos
Sequência de Aminoácidos/genética , Proteínas Morfogenéticas Ósseas/genética , Proteínas Morfogenéticas Ósseas/farmacologia , Regeneração Óssea/efeitos dos fármacos , Substitutos Ósseos , Proteínas de Transporte/genética , Materiais Revestidos Biocompatíveis , Colágeno , Técnicas Genéticas , Variação Genética/genética , Mutação/genética , Osseointegração/efeitos dos fármacos , Próteses e Implantes , Fator de Crescimento Transformador beta , Animais , Proteína Morfogenética Óssea 2 , Relação Dose-Resposta a Droga , Humanos , Masculino , Microrradiografia , Microscopia de Fluorescência , Terminação Traducional da Cadeia Peptídica/genética , Ratos , Ratos Sprague-Dawley
2.
Biochemistry ; 37(45): 15908-17, 1998 Nov 10.
Artigo em Inglês | MEDLINE | ID: mdl-9843396

RESUMO

The multiple mutations associated with high-level AZT resistance (D67N, K70R, T215F, K219Q) arise in two separate subdomains of the viral reverse transcriptase (RT), suggesting that these mutations may contribute differently to overall resistance. We compared wild-type RT with the D67N/K70R/T215F/K219Q, D67N/K70R, and T215F/K219Q mutant enzymes. The D67N/K70R/T215F/K219Q mutant showed increased DNA polymerase processivity; this resulted from decreased template/primer dissociation from RT, and was due to the T215F/K219Q mutations. The D67N/K70R/T215F/K219Q mutant was less sensitive to AZTTP (IC50 approximately 300 nM) than wt RT (IC50 approximately 100 nM) in the presence of 0.5 mM pyrophosphate. This change in pyrophosphate-mediated sensitivity of the mutant enzyme was selective for AZTTP, since similar Km values for TTP and inhibition by ddCTP and ddGTP were noted with wt and mutant RT in the absence or in the presence of pyrophosphate. The D67N/K70R/T215F/K219Q mutant showed an increased rate of pyrophosphorolysis (the reverse reaction of DNA synthesis) of chain-terminated DNA; this enhanced pyrophosphorolysis was due to the D67N/K70R mutations. However, the processivity of pyrophosphorolysis was similar for the wild-type and mutant enzymes. We propose that HIV-1 resistance to AZT results from the selectively decreased binding of AZTTP and the increased pyrophosphorolytic cleavage of chain-terminated viral DNA by the mutant RT at physiological pyrophosphate levels, resulting in a net decrease in chain termination. The increased processivity of viral DNA synthesis may be important to enable facile HIV replication in the presence of AZT, by compensating for the increased reverse reaction rate.


Assuntos
Difosfatos/farmacologia , Transcriptase Reversa do HIV/antagonistas & inibidores , Transcriptase Reversa do HIV/genética , HIV-1/efeitos dos fármacos , Polímeros/metabolismo , Processamento de Proteína Pós-Traducional/genética , Zidovudina/farmacologia , Catálise/efeitos dos fármacos , DNA Viral/metabolismo , Difosfatos/metabolismo , Resistência Microbiana a Medicamentos/genética , Foscarnet/farmacologia , HIV-1/enzimologia , HIV-1/genética , Mutagênese Sítio-Dirigida , Terminação Traducional da Cadeia Peptídica/efeitos dos fármacos , Terminação Traducional da Cadeia Peptídica/genética , Fenótipo , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Inibidores da Transcriptase Reversa/farmacologia , Moldes Genéticos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA